Abstract
E Hamelmann, ED Bateman, C Vogelberg. J Allergy Clin Immunol. 2016;138(2):441–450.e8 Phase II studies in children and adolescents have demonstrated that tiotropium is an effective add-on to inhaled corticosteroid (ICS) maintenance therapy. This study sought to assess the safety and efficacy of once-daily tiotropium Respimat added to ICS in a phase III trial in adolescents with moderate symptomatic asthma. Eligible patients were aged 12–17 years with histories of asthma of >3 months and who were symptomatic at screening, as defined by the 7-question Asthma Control Questionnaire (ACQ-7). Patients were required to have been receiving ICS +/− long-acting β agonist (LABA) or leukotriene receptor antagonist (LTRA), FEV1 …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
